NasdaqGS:GHHealthcare
The Bull Case For Guardant Health (GH) Could Change Following ACS Endorsement Of Shield Blood Test
In late May 2026, Guardant Health announced that its FDA-approved Shield blood test was added to the American Cancer Society’s updated colorectal cancer screening guidelines for average-risk adults 45 and older who decline or have not completed existing stool-based or visual exams.
This endorsement positions Shield as a guideline-backed, blood-based option that could help close the screening gap for tens of millions of currently unscreened Americans, potentially broadening clinical use of...